National Pharmaceutical Pricing Authority, NPPA has revised the ceiling price of 883 scheduled formulations.The Authority in its meeting noted with satisfaction that the supply disruption of active pharmaceutical ingredients caused by COVID-19 outbreak is returning to normalcy.
Government is regulating 24 classes of medical devices which have been notified and regulated as drugs under Drugs and Cosmetics Act, 1940 and and Drugs Cosmetics Rules, 1945. Remaining non-scheduled medical devices which are notified and regulated as drugs, NPPA is currently monitoring Maximum Retail Prices to ensure that no manufacturer and importers can increase the price more than ten per cent in preceding twelve months.
The NPPA in its order stated that all medical devices shall be governed under the provisions of the Drugs (Prices Control) Order, 2013 which come into effect from today. All medical devices shall be regulated by the government as drugs for quality control and price monitoring
NPPA said, no unusual price fluctuations in price of inputs for medicines, amid COVID-19 outbreak has been reported so normal price revisions have been allowed. The revised prices is applicable from today and the detail of revised prices is available on NPPA’s website
www.nppaindia.nic.in.
